NCT07611019
Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial
At risk: Primary completion moved at least 4 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 4 more changesShow less
- Eligibility criteria expanded, about 10 words
- Primary and study completion pushed from Jul 2028 to Dec 2028
- Secondary endpoints revised (7)
- Publications: details revised at 3 of 3 entries
- Notable Trial status changed: Not Yet Recruiting → Enrolling by Invitation
- Study sites: 0 to 1
- Start date changed from estimate of Jun 2026 to Jul 6, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants will receive colchicine 0.5 mg orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).
Participants will receive an identically appearing placebo tablet orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).
Drugs: Colchicine 0.5 MG oral tablet twice daily, Placebo Oral Tablet
Sites
1 site in 1 country
- National Taiwan University HospitalTaipei, Taiwan